Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02946034 · ClinicalTrials.gov registry record · Phase 4
Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT02946034: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT02946034 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02946034, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
Open-label experimental trial of 12 weeks of Viekira Pak treatment ± ribavirin or Mavyret for adults with chronic kidney disease and hepatitis C.
Interventions
- DRUG Mavyret
- DRUG Viekira Pak ± ribavirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2020-09-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02946034
The ClinicalTrials.gov registry entry for NCT02946034 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mavyret is the first listed.
NCT02946034 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02946034 about?
NCT02946034 is a clinical study titled "Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C". Open-label experimental trial of 12 weeks of Viekira Pak treatment ± ribavirin or Mavyret for adults with chronic kidney disease and hepatitis C.
What is the current status of trial NCT02946034?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2017-02-01. Estimated completion is 2020-09-16.
What interventions are being tested in trial NCT02946034?
The interventions under investigation include: Mavyret (DRUG), Viekira Pak ± ribavirin (DRUG).
Who is sponsoring clinical trial NCT02946034?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.